A Meal Replacement Program for the Treatment of Obesity: A Cost-Effectiveness Analysis from the Swiss Payer's Perspective.

Mark NuijtenLivia DainelliBahareh Rasouli Krysmaru Araujo TorresMoreno PeruginiAgnieszka Marczewska

Published in: Diabetes, metabolic syndrome and obesity : targets and therapy (2021)

OPTI program is a dominant strategy compared to "no intervention" and liraglutide 3 mg as it leads to both cost savings and QALY gain. Therefore, reimbursing the OPTI program for patients with obesity would be cost-effective for Swiss payers.

Keyphrases

quality improvement
insulin resistance
metabolic syndrome
weight loss
type diabetes
randomized controlled trial
high fat diet induced
weight gain
skeletal muscle
physical activity
combination therapy
data analysis